Peer-influenced content. Sources you trust. No registration required. This is HCN.

The New England Journal of MedicineEmpagliflozin in Patients with Chronic Kidney Disease

This trial including more than 6,500 patients randomized to empagliflozin or placebo and followed for a median of 2 years. Progression of kidney disease or death from cardiovascular causes was monitored over the course of the trial. Those outcomes occurred in approximately 13% of patients in the empagliflozin group versus approximately 17% of patients in the placebo group.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form